BANGKOK (Reuters) – Thai researchers plan to begin human trials of a possible vaccine for the new coronavirus in November and are preparing 10,000 doses, a senior authorities stated on Sunday, going for a vaccine that could be all set for use by late next year.
SUBMIT PHOTO: A lady holds a little bottle identified with a “Vaccine COVID-19″ sticker label and a medical syringe in this illustration taken April 10, 2020. REUTERS/Dado Ruvic/Illustration/.
Following beneficial outcomes in trials on primates, the next step is to make dosages for human trials, stated Kiat Ruxrungtham, director of the Bangkoks Chulalongkorn University vaccine advancement program.
” At initially we were going to send them in June, but it was difficult to plan everything,” Kiat informed a news conference.
There are no authorized vaccines for the infection that triggers COVID-19, however 19 candidates are being tracked in human beings globally. China is leading the race, with an experimental vaccine by Sinovac Biotech Ltd (SVA.O).
Thailands very first center must complete production in October and send out the products to a 2nd center, which should finish by November, he stated. Initially the earliest target was September, but Kiat said not adequate vaccine can be prepared by then.
Facilities in San Diego and Vancouver will produce 10,000 dosages for the trials for 5,000 individuals. The very first group, aged 18 to 60, will receive various dosages of the vaccine, he said.
The trials will not accept volunteers “till we get approval from the Thai Food and Drug Administration and an ethics committee,” Kiat said.
Thai business BioNet-Asia is preparing its centers for massive production if the trials show successful, he said.
” If everything goes according to plan, the vaccine will be prepared for Thailand in the 4th or 3rd quarter next year,” Kiat said.
Thailand on Sunday had a total of 3,217 validated infections, with no local transmissions reported in over a month, and 58 COVID-19 deaths.
Reporting by Chayut Setboonsarng; Editing by William Mallard.
Our Standards: The Thomson Reuters Trust Principles.